胸与肺高血压相关的肺高血压
Yuliang Long1, Wei Li2, Yingnan Bai1
1Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China.
勃拉迪卡迪引起的肺高血压 (PH) 可以通过增加心率来逆转. 在患有心房动和PH的患者中植入心脏起器,表明肺动脉压力降低,心率升高.
科学领域:
- 心脏病学 心脏病学
- 肺部医学 肺部医学
- 电子生理学 电子生理学
背景情况:
- 目前肺高血压 (PH) 的指导方针侧重于高输出条件,忽略了勃拉迪卡迪引起的低流PH.
- 胸,特别是严重的胸 (<50bpm),可能是PH的可逆原因.
研究的目的:
- 为了研究心率节拍对患有心房动和慢心室反应的患者肺高血压的影响.
- 探索勃拉迪卡迪引起的PH作为可治疗的表型.
主要方法:
- 一个病例研究的患者心房动,缓慢的心室反应,和PH.
- 在植入心脏起器之前和之后进行血液动力学评估,以评估心率对肺动脉压力的影响.
- 在心脏起器植入后对心脏功能指数的监测.
主要成果:
- 植入心脏起器导致心率增加.
- 血液动力学评估显示,随着心率的增加,肺动脉压力逐渐下降.
- 手术后心脏功能指数有所改善.
结论:
- 通过节奏来实现心率升高可能是心房动与勃拉迪卡迪引起的PH的治疗策略.
- 个性化的高心率节奏可以改善心脏输出,减少肺血管抵抗,降低肺动脉压力.
相关概念视频
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Embolism I: Introduction
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...


